<DOC>
	<DOCNO>NCT02419105</DOCNO>
	<brief_summary>The overall purpose study test individual combine effect transdermal testosterone and/or Vitamin D reduce fall risk improve function pre-frail hypogonadal senior men .</brief_summary>
	<brief_title>Effects Transdermal Testosterone and/or Monthly Vitamin D Fall Risk Pre -- frail Hypogonadal Seniors</brief_title>
	<detailed_description>Background : One challenge demographic change enormous personal economic burden fall consequence senior population . Thirty percent adult 65 year old 40 - 50 % age 80 year old fall per year . Serious injury occur 10 - 15 % fall , result fracture 5 % hip fracture 1-2 % case . As independent determinant functional decline , fall lead 40 % nursing home admission . Several study estimate prevalence low testosterone level ( hypogonadism ) old men 20 % age 60 . This proportion increase Baltimore Longitudinal Study Aging decade ( 30 % age 70 50 % age 80 ) . Low testosterone level associate decreased strength , impaired physical performance , increase risk fall , , thus , low testosterone may contribute frailty syndrome old men . Current study focus healthy , community dwell men high level function . Our trial aim enrol pre-frail senior men risk lose autonomy . Further , population also relevant muscle health fall high prevalence vitamin D deficiency . Dose Rationale : The investigator choose 75 mg testosterone/day minimally sufficient dose shift 90 % participant total testosterone level least 16.86 nmol/l ( low end third quartile pilot trial fall reduction significant -- Bischoff-Ferrari et al . ; Osteoporosis International 2008 ) . Additionally , dose choose cardiovascular safety summarize 2013 review . The investigator choose 24000 IU/month vitamin D ( equivalent 800 IU vitamin D per day ) current recommend dose vitamin D evidence fall reduction . To allow standard care give 50 % participant randomize vitamin D supplementation - participant allow take 800 IU vitamin D per day addition study medication . Randomization : Participants randomize baseline clinical visit use computer-based randomization procedure . Willing eligible participant randomize one four treatment group stratify age ( 2 group : 75 - 79 80+ ) . Within stratum , treatment assignment generate block 8 individual , 2 individual 4 treatment group . Blinding : Study medication label unique randomization code respective company . The code inaccessible data set frozen study unblinded . All study package look identical , except randomization code label . Follow-up : Follow-up 12 month 3 clinical ( Baseline , 6 12 month ) 4 ( 2 , 4 , 8 10 month ) phone call visit . Determination Sample Size : The sample size 168 senior participant choose sufficient power primary endpoint ( odds fall ) effect testosterone treatment . Under assumption assume additive effect 2 intervention ( testosterone vitamin D ) , expect investigator pilot study , 89 % power primary endpoint `` number participant sustain least 1 fall '' . This computation assume difference proportion faller -0.24 ( specifically , 0.38 versus 0.62 - base investigator pilot study ) . If 17 % participant would contribute data ( total n = 140 ) , investigator would still 82 % power detect difference . Rate fall : assumption , propose sample size 84 84 two group , study power least 90.6 % yield statistically significant result rate fall . This computation assume mean difference rate fall -1.0 ( correspond mean 0.9 versus 1.9 ) common within-group standard deviation 2.0 ( base standard deviation estimate 2.2 1.7 ) . Planned Analyses : Primary analysis conduct accord intention treat ( ITT ) principle . Every study participant randomize receive study treatment package baseline clinical visit part primary analysis population . In addition primary ITT analysis , data analyze participant demonstrate acceptable adherence study protocol . The per protocol analysis treat sensitivity analysis . The per protocol analysis population include participant : Attended least 1 2 follow-up clinical visit ; Participated least 2 4 follow-up phone call ; Took least 80 % study medication ( ) confirm count use bottle drink solution count weight use transdermal gel container ; take additional vitamin D calcium supplement dose exceed stipulate exclusion criterion . All assessment treatment effect efficacy analysis base intent-to-treat principle . All endpoint variable summarize treatment group . N , Mean , Standard Deviation , Minimum Maximum summarize continuous endpoint variable Number Percentage summarize categorical endpoint variable . All endpoint test 2-sided 5 % significance level ( α = 0.05 , 2-sided ) . Two type model run analysis . Minimally adjusted model include age , body mass index , baseline serum level total testosterone 25-hydroxyvitamin D ; fully adjust model addition parameter include minimally adjust model also include number comorbidities , cognitive function , additional potential confounders baseline analysis justifies inclusion . Each model initially check possible interaction study treatment . If interaction find , interaction term drop simplified model use estimate separate effect study treatment .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Men document total testosterone level &lt; 11.30 nmol/l 2 . Able come study centre ( Communitydwelling institutionalize ) 3 . Age 65+ year 4 . At high risk fall 5 . Body mass index &gt; 18.0 &lt; 35.0 kg/m2 6 . Understands German read write plus able read , understand , complete questionnaire test . 7 . Willingness limit additional vitamin D3 intake maximum 800 IU per day 8 . Willingness limit calcium supplement intake 500 mg/day 9 . Willingness stop active vitamin D metabolites 10 . Willingness forgo additional use/application testosterone product duration trial . 11 . Participant understands study procedure , alternative treatment available risk involve study voluntarily agree participate give write informed consent . 12 . Participant meet routine clinical laboratory safety screen test perform screen visit . 13 . Participant able willing perform study test , attend require office visit , provide blood urine sample . 14 . Participant able apply testosterone/placebo gel able drink vitamin D/placebo solution . 15 . Participant mentally competent ( judicious ) define score &gt; 24 Folstein 's mini mental state examination ( MMSE ) screen visit . 1 . Contraindications class drug study , e.g . know hypersensitivity allergy class drug investigational product 2 . Treatment vitamin Kantagonists , insulin , adrenocorticotropic hormone ( ACTH ) , corticosteroid ( &gt; 5mg/d ) 3 . Elevated ( ≥ 4.0 ng/ml ) prostatespecific antigen level ( screen ) and/or palpable sign prostate cancer 4 . Palpable sign breastcancer 5 . Haemoglobin ≤ 100 g/l 6 . Haematocrit ≥ 0.50 L/L 7 . Liver function value ( alanine aminotransferase , aspartate aminotransferase , Gammaglutamyl transferase , alkaline phosphatase ) 3 time upper limit normal . 8 . Consumption &gt; 800 IU vitamin D day 6 month prior enrolment . Provision : person enrol soon mean intake last 6 month since last dose ≤ 800 IU . 9 . Elevated serum calcium ≥ 2.60 mmol/l ( adjust albumin ) 10 . Estimated ( Cockcroft Gault formula ) creatinine clearance ≤ 30 ml/min 11 . Severe visual hearing impairment 12 . History cancer &lt; 5 year prior sign inform consent , except adequately treat basal cell squamous cell skin cancer 13 . Myocardial infarction last 3 month , unstable angina pectoris and/or exertional dyspnoea &gt; =NYHA III 14 . Treatment worthy untreated sleep apnoea chronic ( obstructive ) pulmonary disease , epilepsy 15 . Significant endstage disease , i.e . genitourinary , cardiovascular , hepatic , renal , endocrine , hematologic , psychiatric , pulmonary disease , , opinion investigator , may pose high risk patient impair patient 's ability complete trial confound result 16 . Uncontrolled hypertension ( blood pressure mm Hg ≥ 180 systolic ≥ 110 diastolic ) 17 . Alcohol abuse alcoholic disease 18 . Participation another interventional research trial within last 6 month prior screen 19 . Severe gait impairment , e.g . due Parkinson 's disease hemiplegia 20 . Previous enrolment current study 21 . Enrolment investigator , his/her family member , employee dependent person</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Falls</keyword>
	<keyword>hypogonadal men</keyword>
	<keyword>Seniors</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Colecalciferol</keyword>
</DOC>